EPHA2 and pancreatic neoplasm: It was shown in multiple preclinical models of ovarian, breast, and pancreatic cancers that inducing EphA2 downregulation by antibody-mediated inhibition of signaling, antibody-mediated downregulation of total EphA2 expression, and siRNA-mediated inhibition of expression the tumor growth is decreased, further prolongs survival and inhibits angiogenesis (43).